$PSFE

Paysafe Wallet Users Rise 8% as iGaming Volume Accelerates

Paysafe reported Q2 results and guidance. Three-month active consumers rose 8% to 7.8 million for a fifth straight quarter. Digital Wallets volume was about $6.6 billion, flat year over year, while revenue per active user fell 5%. Merchant Solutions volume rose 5% to $37.3 billion and revenue to $246.1 million. iGaming grew 17% and processing volumes accelerated. Paysafe reaffirmed full-year revenue guidance.

Original reporting
Published Aug 13, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Paysafe Wallet Users Rise 8% as iGaming Volume Accelerates — source image
Decision brief

The 30-second read

$PSFEBullishMed
01

Why it matters

Traders can use the quantified active-user growth, iGaming processing acceleration (June and July), and the reaffirmed full-year guidance to reassess 2H growth expectations and near-term momentum trades.

02

Market read

Same-day earnings commentary points to accelerating iGaming processing volumes and continued active-user growth, partially offset by flat wallet volume and lower revenue per active user.

03

What to watch

The article mentions data licensing and debt/litigation settlement, but provides limited detail on margins, churn drivers, and how much of the 2H revenue bridge is already contracted versus pipeline.

Relevance 7/10Novelty 6/10Timing: reported during Aug. 13 Q2 earnings call, with shares up 3% early trading

Background

Paysafe’s Q2 update includes consumer and merchant KPIs, commentary on SMB performance, and a 2H revenue outlook framework.

Company-level read

Ticker impact

$PSFEBullishMedium confidence
Context

Paysafe reported 8% YoY active consumer growth to 7.8M, reaffirmed full-year guidance, and cited iGaming processing volume acceleration into 2H.

Expected impact

Likely supportive for PSFE shares near-term, especially for traders focused on 2H iGaming and consumer engagement trends.

Evidence & confidence

The article is a same-day earnings update with multiple quantified KPIs and a reaffirmed outlook, plus a specific 2H revenue bridge framework. However, it does not provide explicit guidance numbers beyond reaffirmation, limiting precision.

Market effects

Supports the payments and iGaming processing theme that wallet engagement and processing volumes are improving, potentially lifting sentiment for adjacent digital payments names.

Highlights Latin America as a key growth driver for active users and wallet growth, reinforcing regional risk-on positioning for LATAM-linked payment flows.

Reinforces ongoing demand for digital wallet and merchant processing infrastructure, with data-licensing as a potential incremental revenue stream.

Counterpoint

Wallet volume stayed roughly flat and average revenue per active user fell 5%, so user growth may not translate into immediate top-line acceleration.

Key entities

  • Paysafe

    Digital wallet and merchant payments provider reporting Q2 KPIs and reaffirming full-year revenue guidance.

  • Bruce Lowthers

    CEO cited double-digit user growth in Latin America and discussed data licensing potential.

  • John Crawford

    CFO cited iGaming growth and outlined a roughly third-by-third 2H revenue contribution framework.

Related articles

$PSFEHigh

Paysafe Ltd (PSFE): Financial results for Q2 2026

Paysafe Ltd (PSFE) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PAYSAFE REPORTS SECOND QUARTER 2026 RESULTS London, UK – August 13, 2026 – Paysafe Limited (NYSE: PSFE) today announced financial results for the second quarter of 2026. Second Quarter 2026 Summary (compared to Q2 2025, unless noted) • Revenue of $447.4m increased 4%

$PSFEMed

Paysafe Ltd (PSFE): Financial results for Q2 2026

Paysafe Ltd (PSFE) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Preliminary Select Financial Results for Q2 2026 Preliminary second quarter select financial results Subject to the finalization of financial reporting processes, revenue for the second quarter of 2026 is estimated to be $447 million, an increase of 4% compared to th

$PLBLMed

Polibeli Group Ltd (PLBL): Financial results for H1 2026

Polibeli Group Ltd (PLBL) furnished an SEC Form 6-K — earnings release. Polibeli Group Ltd Announces Unaudited Financial Results for the six months ended June 30, 2026 On September 21, 2026, Polibeli Group Ltd (the “Company”) announced its unaudited financial results for the six months ended June 30, 2026. Business and Strategic Update ● As of the da

$VICRHighAI 8/10

Why is Vicor stock surging today?

Vicor Corporation's stock rose 12.3% after hours after raising its Q3 2026 revenue growth guidance from nearly 10% to over 20%, driven by royalties from its VPD licensing program. Four major companies have licensed the technology, and the CEO noted potential supply disruptions for unlicensed suppliers. The company also recently authorized a $150M share buyback and acquired properties for AI-driven demand. The Nasdaq closed at a record high, led by AI stocks, but broader indices were unchanged.

$OPTULow

Optimum Communications, Inc. (OPTU): Results of Operations and Financial Condition

Optimum Communications, Inc. (OPTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. The information appearing below under Item 4.02 regarding certain previously reported financial information of Optimum Communications, Inc. (the "Company") for the fiscal year ended December 31, 2025, and the fiscal quarter

$ABVXMedAI 8/10

EQS-News: ABIVAX: Abivax Presents Business Updates and First Half 2026 Financial Results

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.